Global API focus Target Hetero’s core business of APIs and intermediates to offer contract manufacturing, custom synthesis, or exclusive supply agreements for high-demand generics and anti-infective portfolios.

COVID-19 antiviral leverage Leverage Hetero’s experience with nirmatrelvir/ritonavir licensing and remdesivir (Covifor) launches to position for future pandemic-related API needs and rapid-response manufacturing capabilities.

Strategic expansions Monitor past and ongoing asset investments and SEZ developments to identify opportunities for joint ventures, land-adjacent manufacturing capacity, or co-located supply chains to reduce time-to-market.

Scale and capacity With a sizable workforce and revenue in the multinational range, propose large-volume API supply, finished dosage contracts, and long-term supply agreements to ensure steady demand and capacity utilization.

Global partnerships Capitalize on Hetero’s partnerships (MPP licensing, RDIF associations) to explore compliant licensing-driven markets, dual-licensing opportunities, and cross-border distribution collaborations.